Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Optimi Health ( (TSE:OPTI) ) just unveiled an update.
Optimi Health has begun early clinical rollout of its naturally derived 5 mg psilocybin capsules for patients with treatment-resistant depression in Australia, marking the first patients of 2026 treated outside sponsor-led clinical trials under the country’s regulated framework. The products are manufactured in Canada to TGA quality standards and supplied via an Australian pharmacy partner, with administration handled by Authorised Prescribers under national rules.
The company is now supplying both psilocybin for depression and MDMA for PTSD into Australia’s regulated medical framework, signalling growing clinical adoption of psychedelic therapies within the Authorised Prescriber Scheme. Treatment data and patient-reported outcomes are being captured in a national registry in partnership with Australian National University, underscoring a structured, data-driven approach that may influence future policy, clinical practice, and broader market acceptance of psychedelic-assisted therapies.
The most recent analyst rating on (TSE:OPTI) stock is a Sell with a C$0.28 price target. To see the full list of analyst forecasts on Optimi Health stock, see the TSE:OPTI Stock Forecast page.
Spark’s Take on TSE:OPTI Stock
According to Spark, TipRanks’ AI Analyst, TSE:OPTI is a Neutral.
The score is primarily held down by weak financial performance (sharp revenue decline, negative gross profit, ongoing losses and cash burn, and higher leverage). Technicals are supportive with price above major moving averages and a positive MACD, but overbought readings (RSI/Stoch) add near-term risk. Valuation is constrained by negative earnings and no provided dividend yield.
To see Spark’s full report on TSE:OPTI stock, click here.
More about Optimi Health
Optimi Health Corp. is a Health Canada-licensed, GMP-compliant pharmaceutical manufacturer specializing in prescribed psychedelic treatments for mental health therapies. From two 10,000-square-foot facilities in British Columbia, the company produces validated MDMA and botanical psilocybin products for regulated channels, including prescription use in Australia and access in Canada through the Special Access Program.
Average Trading Volume: 101,972
Technical Sentiment Signal: Buy
Current Market Cap: C$30.38M
For a thorough assessment of OPTI stock, go to TipRanks’ Stock Analysis page.